







### REMARKS

In the Final Office Action of July 14, 2011, claims 40, 41, 43, 44, 46, and 52-55 were rejected under 35 USC 102(e) over Adje et al. Claims 47-51, and 56-58 were objected to for being dependent on a rejected base claim. Claim 59 was withdrawn from consideration.

The Patent Office has taken the position that the Adje et al. reference anticipates compound (I) of the invention, in which:



Further, it appears possible that compounds of Examples 17, 18, and 19 of Adje et al., in which  $R_5 = R_6 = F$ , also anticipate the compounds of the invention when  $p = 2$ .

Furthermore, it appears that there is a potential overlapping of compounds when  $R_9$  is  $(C_1-C_6)$ alkyl or acyl.

Claim 40 has now been amended to exclude these possibilities.

As recited in claim 40, the present proviso states that when  $p$  is 2,  $R_3$  is cyano or  $(C_1-C_6)$  alkoxy and  $R_8$  is hydrogen,

then one R<sub>9</sub> is selected from the group consisting of hydroxy, cyano, halogen, nitro, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, trifluoromethyl, acyl, NR<sub>10</sub>R<sub>11</sub>, OSO<sub>2</sub>NR<sub>10</sub>R<sub>11</sub>, NR<sub>12</sub>SO<sub>2</sub>NR<sub>10</sub>R<sub>11</sub>, and CO<sub>2</sub>R<sub>10</sub>, and the other R<sub>9</sub> is selected from the group consisting of hydroxy, nitro, NR<sub>10</sub>R<sub>11</sub>, OSO<sub>2</sub>NR<sub>10</sub>R<sub>11</sub>, NR<sub>12</sub>SO<sub>2</sub>NR<sub>10</sub>R<sub>11</sub>, and CO<sub>2</sub>R<sub>10</sub>.

Accordingly, it is believed that claim 40 does not read on Adje et al., and withdrawal of the rejection over Adje et al. is respectfully requested.

A number of other amendments have been made to the claims. Claim 56 has been amended to include the compound of Example 21 set forth in claim 59. Claim 59 has been canceled.

The compound 5-{[N-(4-cyanophenyl)-N-(1H-imidazol-1-yl)amino]methyl}-2-methoxybenzoic acid was previously deleted from claim 56, as not being within the scope of claim 40. However, it is clear that this compound is indeed within the scope of compounds of claim 40 in which:

R<sub>1</sub> = R<sub>2</sub> = H;

R<sub>3</sub> = cyano;

R<sub>4</sub> = H;

R<sub>8</sub> = H;

Q = (CH<sub>2</sub>)<sub>n</sub>, where n = 1

p = 2; and

R<sub>9</sub> = OMe/COOH


Finally, the last two compounds of claim 56, which were erroneously added by Supplemental Amendment filed on November

24, 2010, have been deleted from claim 56. These two compounds are, in fact, already present as the first two compounds listed in claim 56, although it is noted that the compound of Example 9, 4-[N-(1H-imidazol-1-yl)-N-(4-**methoxyphenyl**)amino]methylbenzonitrile, was incorrectly set forth as 4-[N-(1H-imidazol-1-yl)-N-(4-**ethoxyphenyl**)amino]methylbenzonitrile in the November 24, 2010, Supplemental Amendment.

No new matter has been added by the present claim amendments.

In view of the above amendments and remarks, Applicant submits that the application is now in condition for allowance, and an early notice to that effect is earnestly solicited.

Respectfully submitted,



October 14, 2011

Malcolm J. MacDonald  
Reg. No. 40,250  
Tel: (703) 837-9600 Ex. 24

Dennison, Schultz & MacDonald  
1727 King St., Suite 105  
Alexandria, VA 22314